Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Therapeutics - Page 37

Therapeutics

Humanigen announced BARDA contract and Expansion of CRADA with U.S. Government for COVID-19
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Humanigen announced BARDA contract and Expansion of CRADA with U.S. Government for COVID-19

On Jan. 22, 2021, Humanigen announced an expansion to the Cooperative Research and Development Agreement (CRADA) that the…

Read More Humanigen announced BARDA contract and Expansion of CRADA with U.S. Government for COVID-19Continue

Cue’s Molecular, point-of-care COVID-19 tests available under HHS and DoD pilot program
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine

Cue’s Molecular, point-of-care COVID-19 tests available under HHS and DoD pilot program

On Jan. 19, 2021, Cue Health announced that its molecular, point-of-care COVID-19 Tests were being distributed to five…

Read More Cue’s Molecular, point-of-care COVID-19 tests available under HHS and DoD pilot programContinue

Mammoth Biosciences secured U.S. DoD award to develop CRISPR-based diagnostics and biosurveillance platforms
Biotechnology | Chemistry | CRISPR | Diagnostics | Genomics | Infectious Disease | Therapeutics

Mammoth Biosciences secured U.S. DoD award to develop CRISPR-based diagnostics and biosurveillance platforms

On Jan. 14, 2021, Mammoth Biosciences announced that it had secured a subcontract with MRIGlobal, the prime contractor…

Read More Mammoth Biosciences secured U.S. DoD award to develop CRISPR-based diagnostics and biosurveillance platformsContinue

Blood test showed promise for early detection of acute heart transplant rejection
Biotechnology | NIH | Therapeutics

Blood test showed promise for early detection of acute heart transplant rejection

On Jan. 13, 2021, researchers announced they had developed a blood test that could make it possible for…

Read More Blood test showed promise for early detection of acute heart transplant rejectionContinue

NIAID scientists studied salmonella swimming behavior as clues to infection
Biotechnology | Infectious Disease | NIH | Therapeutics

NIAID scientists studied salmonella swimming behavior as clues to infection

On Jan. 13, 2021, National Institutes of Health scientists and their colleagues announced they had identified a S….

Read More NIAID scientists studied salmonella swimming behavior as clues to infectionContinue

Mateon announced positive interim results from its ARTI-19 clinical trial evaluating ARTIVeda against COVID-19
Biotechnology | COVID-19 | Therapeutics

Mateon announced positive interim results from its ARTI-19 clinical trial evaluating ARTIVeda against COVID-19

On Jan. 13, 2021, Mateon Therapeutics reported positive interim results from its ARTI-19 clinical trial evaluating ARTIVedaTM against…

Read More Mateon announced positive interim results from its ARTI-19 clinical trial evaluating ARTIVeda against COVID-19Continue

SIGA announced Public Health Agency of Canada contract to purchase $33 million of Oral TPOXX
Therapeutics

SIGA announced Public Health Agency of Canada contract to purchase $33 million of Oral TPOXX

On Jan. 13, 2021, SIGA Technologies announced that the Public Health Agency of Canada had awarded a contract…

Read More SIGA announced Public Health Agency of Canada contract to purchase $33 million of Oral TPOXXContinue

Rising protocol design complexity reported driving rapid growth in clinical trial data volume
Biotechnology | Diagnostics | Disease | Non-Profit Research | Therapeutics | Women's Health

Rising protocol design complexity reported driving rapid growth in clinical trial data volume

On Jan. 12, 2021, the Tufts Center for the Study of Drug Development reported that ever more complex…

Read More Rising protocol design complexity reported driving rapid growth in clinical trial data volumeContinue

Roche’s Xofluza approved by the EC for treatment of influenza, first new influenza antiviral in almost 20 years
Biotechnology | Infectious Disease | Influenza | Therapeutics

Roche’s Xofluza approved by the EC for treatment of influenza, first new influenza antiviral in almost 20 years

On Jan. 11, 2021, Roche announced that the European Commission (EC) had approved Xofluza (baloxavir marboxil) for the…

Read More Roche’s Xofluza approved by the EC for treatment of influenza, first new influenza antiviral in almost 20 yearsContinue

FDA cleared initiation of the Editas Medicine’s EDIT-301 clinical trial using CRISPR/Cas12a gene editing
Biotechnology | CRISPR | FDA | Therapeutics

FDA cleared initiation of the Editas Medicine’s EDIT-301 clinical trial using CRISPR/Cas12a gene editing

On Jan. 11, 2021, Editas Medicine announced the U.S. Food and Drug Administration (FDA) had cleared the initiation…

Read More FDA cleared initiation of the Editas Medicine’s EDIT-301 clinical trial using CRISPR/Cas12a gene editingContinue

American Cancer Society reported largest one-year drop in cancer mortality from 1991-2017
Biotechnology | Diagnostics | Disease | Oncology | Radiology | Therapeutics

American Cancer Society reported largest one-year drop in cancer mortality from 1991-2017

On Jan. 8, 2021, the American Cancer Society reported that the death rate from cancer in the U.S….

Read More American Cancer Society reported largest one-year drop in cancer mortality from 1991-2017Continue

In vitro study showed Pfizer-BioNTech COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 with mutation
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine

In vitro study showed Pfizer-BioNTech COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 with mutation

On Jan. 8, 2021, Pfizer and BioNTech announced results from an in vitro study conducted by Pfizer and…

Read More In vitro study showed Pfizer-BioNTech COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 with mutationContinue

Twist Bioscience supplied Centers for Disease Control and Prevention with custom SARS-CoV-2 synthetic RNA controls
Biotechnology | CDC | COVID-19 | Diagnostics | Infectious Disease | Influenza | Therapeutics

Twist Bioscience supplied Centers for Disease Control and Prevention with custom SARS-CoV-2 synthetic RNA controls

On Jan. 7, 2021, Twist Bioscience announced it would supply the U.S. Centers for Disease Control and Prevention…

Read More Twist Bioscience supplied Centers for Disease Control and Prevention with custom SARS-CoV-2 synthetic RNA controlsContinue

CytoDyn research on critically Ill COVID-19 patients published in Journal of Translational Autoimmunity
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

CytoDyn research on critically Ill COVID-19 patients published in Journal of Translational Autoimmunity

On Dec. 31, 2020, CytoDyn announced a research manuscript submitted by Nicholas J. Agresti, M.D. had been accepted…

Read More CytoDyn research on critically Ill COVID-19 patients published in Journal of Translational AutoimmunityContinue

Mateon global study for OT-101/ TGF-inhibitor against COVID-19 treated its first patient
Biotechnology | COVID-19 | Therapeutics

Mateon global study for OT-101/ TGF-inhibitor against COVID-19 treated its first patient

On Dec. 30, 2020, Mateon Therapeutics announced that it had enrolled and treated its first sentinel Part 1…

Read More Mateon global study for OT-101/ TGF-inhibitor against COVID-19 treated its first patientContinue

NIH study uncovered blood vessel damage and inflammation in COVID-19 patients’ brains but no infection
COVID-19 | Neurology | NIH | Therapeutics

NIH study uncovered blood vessel damage and inflammation in COVID-19 patients’ brains but no infection

On Dec. 30, 2020, the NIH researchers announced that an in-depth study of how COVID-19 affects a patient’s…

Read More NIH study uncovered blood vessel damage and inflammation in COVID-19 patients’ brains but no infectionContinue

Medigen Vaccines obtained TFDA phase 2 IND approval for COVID19 vaccine
Biotechnology | COVID-19 | FDA | NIH | Therapeutics

Medigen Vaccines obtained TFDA phase 2 IND approval for COVID19 vaccine

On Dec. 30, 2020, Medigen Vaccine Biologics announced that it had obtained TFDA Phase 2 IND approval of…

Read More Medigen Vaccines obtained TFDA phase 2 IND approval for COVID19 vaccineContinue

FDA approved first generic of drug used to treat severe hypoglycemia
Biotechnology | Disease | FDA | Therapeutics

FDA approved first generic of drug used to treat severe hypoglycemia

On Dec. 28, 2020,  the U.S. Food and Drug Administration approved the first generic of glucagon for injection…

Read More FDA approved first generic of drug used to treat severe hypoglycemiaContinue

The Serum Institute of India launched India’s first indigenously developed pneumococcal vaccine
Biotechnology | Disease | Therapeutics | Vaccine

The Serum Institute of India launched India’s first indigenously developed pneumococcal vaccine

On Dec. 28, 2020, Serum Institute of India announced the launch of India’s first indigenously developed pneumococcal vaccine…

Read More The Serum Institute of India launched India’s first indigenously developed pneumococcal vaccineContinue

Sorrento announced it had submitted an EUA application to the FDA for COVI-STIX rapid test for detection of SARS-CoV-2 antigen
Biotechnology | COVID-19 | FDA | Therapeutics

Sorrento announced it had submitted an EUA application to the FDA for COVI-STIX rapid test for detection of SARS-CoV-2 antigen

On Dec. 22, 2020, Sorrento Therapeutics announced that an Emergency Use Authorization (EUA) Application had been submitted to…

Read More Sorrento announced it had submitted an EUA application to the FDA for COVI-STIX rapid test for detection of SARS-CoV-2 antigenContinue

RedHill’s phase 2/3 COVID-19 study of opaganib passed second DSMB with unanimous recommendation
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

RedHill’s phase 2/3 COVID-19 study of opaganib passed second DSMB with unanimous recommendation

On Dec. 22, 2020, RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640)1…

Read More RedHill’s phase 2/3 COVID-19 study of opaganib passed second DSMB with unanimous recommendationContinue

Cocrystal Pharma selected lead compound for further development against Coronaviruses
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

Cocrystal Pharma selected lead compound for further development against Coronaviruses

On Dec. 22, 2020, Cocrystal Pharma announced the selection of CDI-45205 as the lead compound for further development…

Read More Cocrystal Pharma selected lead compound for further development against CoronavirusesContinue

European Commission approved Aimmune’s PALFORZIA as first-ever treatment for peanut allergy in the EU
Agriculture | Biotechnology | Diagnostics | Disease | Therapeutics

European Commission approved Aimmune’s PALFORZIA as first-ever treatment for peanut allergy in the EU

On Dec. 21, 2020, Aimmune Therapeutics announced that the European Commission (EC) had approved PALFORZIA [defatted powder of…

Read More European Commission approved Aimmune’s PALFORZIA as first-ever treatment for peanut allergy in the EUContinue

Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY

On Dec. 19, 2020, Pfizer and BioNTech announced they supplying an additional 100 million doses of COMIRNATY the…

Read More Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATYContinue

FDA approved first adjuvant therapy for most common type of lung cancer
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics

FDA approved first adjuvant therapy for most common type of lung cancer

On Dec. 18, 2020, the the U.S. Food and Drug Administration (FDA) approved AstraZeneca’s Tagrisso (osimertinib) as the…

Read More FDA approved first adjuvant therapy for most common type of lung cancerContinue

National Research Council of Canada supported development of 4 COVID-19 therapeutic candidates
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

National Research Council of Canada supported development of 4 COVID-19 therapeutic candidates

On Dec. 18, 2020, the National Research Council of Canada (NRC) announced it was providing advisory services and…

Read More National Research Council of Canada supported development of 4 COVID-19 therapeutic candidatesContinue

Lilly began pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Lilly began pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico

On Dec. 18, 2020, Eli Lilly announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in…

Read More Lilly began pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New MexicoContinue

RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical model
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical model

On Dec. 15, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed…

Read More RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical modelContinue

Aurinia and Lonza announced exclusive agreement for dedicated Voclosporin manufacturing capacity
Biotechnology | COVID-19 | Infectious Disease | Organ Transplant | Pharmaceutical | Therapeutics

Aurinia and Lonza announced exclusive agreement for dedicated Voclosporin manufacturing capacity

On Dec. 15, 2020, Aurinia Pharmaceuticals announced the funding and initiation of an open-label exploratory trial evaluating the…

Read More Aurinia and Lonza announced exclusive agreement for dedicated Voclosporin manufacturing capacityContinue

INOVIO to develop DNA-encoded monoclonal antibody (dMAb) candidates to treat COVID-19
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

INOVIO to develop DNA-encoded monoclonal antibody (dMAb) candidates to treat COVID-19

On Dec. 15, 2020, Inovio Pharma announced the company and a team of scientists from The Wistar Institute,…

Read More INOVIO to develop DNA-encoded monoclonal antibody (dMAb) candidates to treat COVID-19Continue

Page navigation

Previous PagePrevious 1 … 35 36 37 38 39 … 115 Next PageNext
  • Categories
  • Timeline
  • Aesthetics
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cardiology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemistry
  • Clinical Research
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Quantum
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Banner Advertising

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search